


Amendment Pursuant to 37 C.F.R. § 1.121

IN THE CLAIMS:

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. (previously presented) A compound in the form of an enantiomer (1R,2R) or (1S,2S) or in the form of a threo diastereoisomer, corresponding to general formula (I)



in which A represents

a group of general formula N-R₁, a group of general formula N⁺(O⁻)R₁ or a group of general formula N⁺(R')R₁, and in which R₁ represents either a hydrogen atom, or a linear or branched (C₁-C₇)alkyl group optionally substituted with one or more fluorine atoms, or a (C₄-C₇)cycloalkyl group, or a (C₃-C₇)cycloalkyl(C₁-C₃)alkyl group, or a phenyl(C₁-C₃)alkyl group optionally substituted with one or two hydroxyl or methoxy groups, or a (C₂-C₄)alkenyl group, or a (C₂-C₄)alkynyl group,

R' represents a linear or branched (C₁-C₇)alkyl group,

X represents a hydrogen atom or one or more substituents chosen from halogen atoms and trifluoromethyl, linear or branched (C₁-C₄)alkyl and (C₁-C₄)alkoxy groups,

R₂ represents either a hydrogen atom, or one or more substituents chosen from halogen atoms and trifluoromethyl, (C₁-C₄)alkyl or (C₁-C₄)alkoxy groups, or amino groups of general formula NR₃R₄ in which R₃ and R₄ each represent, independently of each other, a hydrogen atom or a (C₁-C₄)alkyl group, or form with the nitrogen atom carrying them a pyrrolidine, piperidine or morpholine ring, or a phenyl group optionally substituted with an atom or a group as defined for the symbol X above,

in the form of a free base or of an addition salt with an acid.

2. (previously presented) A compound according to Claim 1 wherein it has the configuration (1S,2S) and in that R₂ represents one or more halogen atoms or trifluoromethyl groups.

3. (previously presented) A compound according to Claim 1 wherein it has the configuration (1R,2R) and in that R₂ represents a halogen atom and an amino group of general formula NR₃R₄ as defined in Claim 1.

4. (cancelled)

1 / 5. (previously presented) A pharmaceutical composition comprising a compound according to Claim 1 combined with an excipient.

6. (original) 2-Chloro-N-[(S)-phenyl-[(2S)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide according to claim 1.

7. (original) 2-Chloro-N-[(S)-phenyl-[(2S)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide hydrochloride 1:1 according to claim 6.

1 2 / 8. (original) A pharmaceutical composition comprising a compound according to Claim 2 combined with an excipient.

1 3 / 9. (original) A pharmaceutical composition comprising a compound according to Claim 3 combined with an excipient.

1 4 / 10. (original) A pharmaceutical composition comprising a compound according to Claim 6 combined with an excipient.

15 **X1.** (original) A pharmaceutical composition comprising a compound according to Claim 7 combined with an excipient.

12. - 16. (cancelled)

4 **X7.** (original) A compound according to claim 1 wherein A represents a group of general formula N-R₁ in which R₁ represents either a hydrogen atom, or a linear or branched (C₁-C₇)alkyl group optionally substituted with one or more fluorine atoms and said compound in the form of a free base or of an addition salt with an acid.

5 **X8.** (original) A compound according to claim 1 which is selected from the group consisting of:

- threo-2-chloro-N-[(1-ethylpiperidin-2-yl)phenylmethyl]-3-trifluoromethylbenzamide hydrochloride;
- threo-2-chloro-N-[(1-ethylpiperidin-2-yl)phenylmethyl]-3-trifluoromethylbenzamide;
- 2-chloro-N-[(1S)-[(2S)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethylbenzamide hydrochloride;
- 2-chloro-N-[(1S)-[(2S)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethylbenzamide;
- threo-4-amino-3-chloro-N-[(1-methylpiperidin-2-yl)phenylmethyl]-5-trifluoromethylbenzamide hydrochloride;
- threo-4-amino-3-chloro-N-[(1-methylpiperidin-2-yl)phenylmethyl]-5-trifluoromethylbenzamide;
- 4-amino-3-chloro-N-[(1R)-[(2R)-1-methylpiperidin-2-yl]phenylmethyl]-5-trifluoromethylbenzamide hydrochloride;

- 4-amino-3-chloro-*N*-[(1*R*)-[(2*R*)-1-methylpiperidin-2-yl]phenylmethyl]-5-trifluoromethylbenzamide;

- threo-2-chloro-*N*-[phenyl(piperidin-2-yl)methyl]-3-trifluoromethylbenzamide hydrochloride;

- threo-2-chloro-*N*-[phenyl(piperidin-2-yl)methyl]-3-trifluoromethylbenzamide;

- 2-chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide hydrochloride;

- 2-chloro-*N*-[(*S*)-phenyl-[(2*S*)-piperidin-2-yl]methyl]-3-(trifluoromethyl)benzamide;

- 2-chloro-*N*-[[1-methyl-1-oxido-piperidin-2-yl](phenyl)methyl]-3-trifluoromethylbenzamide; and

- 2(*S*)-2[(1*S*)-[[2-chloro-3-(trifluoromethyl)benzoyl]amino](phenyl)methyl]-1,1-dimethylpiperidinium iodide or a pharmaceutically acceptable salt thereof.

8 19. (original) 2-chloro-*N*-[(1*S*)-[(2*S*)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethylbenzamide according to claim 1.

9 20. (original) 2-chloro-*N*-[(1*S*)-[(2*S*)-1-methylpiperidin-2-yl]phenylmethyl]-3-trifluoromethylbenzamide hydrochloride 1:1 according to claim 1.

10 21. (original) 4-amino-3-chloro-*N*-[(1*R*)-[(2*R*)-1-methylpiperidin-2-yl]phenylmethyl]-5-trifluoromethylbenzamide hydrochloride 1:1 according to claim 1.

15 22. (original) A pharmaceutical composition comprising a compound according to Claim 18 combined with an excipient.

- 16 23. (original) A pharmaceutical composition comprising a compound according to Claim 19 combined with an excipient.
- 17 24. (original) A pharmaceutical composition comprising a compound according to Claim 20 combined with an excipient.
- 18 25. (original) A pharmaceutical composition comprising a compound according to Claim 21 combined with an excipient.
26. (currently amended) A method for the treatment of a disorder associated with ~~glyt1 glycine transporter disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine~~, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 1.
27. (currently amended) A method for the treatment of a disorder associated with ~~glyt1 glycine transporter disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine~~, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 2.
28. (currently amended) A method for the treatment of a disorder associated with ~~glyt1 glycine transporter disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine~~, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 6.

29. (currently amended) A method for the treatment of a disorder associated with glyt1 glycine transporter disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 7.
30. (currently amended) A method for the treatment of a disorder associated with glyt1 glycine transporter disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 17.
31. (currently amended) A method for the treatment of a disorder associated with glyt1 glycine transporter disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 18.
32. (currently amended) A method for the treatment of a disorder associated with glyt1 glycine transporter disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 19.

33. (currently amended) A method for the treatment of a ~~disorder associated with glyt1~~ ~~glycine transporter disorder selected from the group consisting of dementia, psychoses, schizophrenia, extrapyramidal symptoms induced by neuroleptics, anxiety, panic attacks, depression, obsessive compulsive disorder, alcohol abuse and migraine,~~ comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 20.

34. (currently amended) A method for the treatment of a ~~disorder associated with glyt2~~ ~~glycine transporter disorder selected from the group consisting of painful muscular contractures in rheumatology, spinal pathology, pain including neurogenic pain, rebellious algia, Parkinson's disease, epilepsy and sleep apnea,~~ comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 1.

35. (currently amended) A method for the treatment of a ~~disorder associated with glyt2~~ ~~glycine transporter disorder selected from the group consisting of painful muscular contractures in rheumatology, spinal pathology, pain including neurogenic pain, rebellious algia, Parkinson's disease, epilepsy and sleep apnea,~~ comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 3.

36. (currently amended) A method for the treatment of a ~~disorder associated with glyt2~~ ~~glycine transporter disorder selected from the group consisting of painful muscular contractures in rheumatology, spinal pathology, pain including neurogenic pain, rebellious algia, Parkinson's disease, epilepsy and sleep apnea,~~ comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 17.

37. (currently amended) A method for the treatment of a disorder associated with glyt2 glycine transporter disorder selected from the group consisting of painful muscular contractures in rheumatology, spinal pathology, pain including neurogenic pain, rebellious algia, Parkinson's disease, epilepsy and sleep apnea, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 18.

38. (currently amended) A method for the treatment of a disorder associated with glyt2 glycine transporter disorder selected from the group consisting of painful muscular contractures in rheumatology, spinal pathology, pain including neurogenic pain, rebellious algia, Parkinson's disease, epilepsy and sleep apnea, comprising administering to a patient in need of said treatment an effective amount of a compound according to Claim 21.